Ascletis Pharma Inc.
ASCLF
Updated: 24/09/2026, 09:14:31
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People's Republic of China.
No summaries found.
- Share price
- $1.20
- Market cap
- $1.26B
- Exchange
- OTC
- Currency
- USD
- CEO
- Jinzi J. Wu
- Employees
- 202
- IPO date
- 19/11/2019
- Beta
- 0.392
- Last dividend
- $0.00
- Day range
- $1.20 – $1.20
- 52-week range
- $1.07 – $2.50
- 1-day performance
- 0.00%
- 1-year performance
- 12.15%
- Current drawdown (1Y)
- -52.00%
- CIK
- N/A
- CUSIP
- G0520K109
- ISIN
- KYG0520K1094
- Created
- 07/12/2025, 02:10:06
- Last update
- 24/09/2026, 09:14:31
Track Ascletis Pharma Inc. with an AI analyst
See which prediction-market events move ASCLF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.